Open Access to Scientific Data & Publications Malcolm Skingle - - PowerPoint PPT Presentation

▶

Apr 09, 2023 164 likes •279 views

Open Access to Scientific Data & Publications Malcolm Skingle CBE DSc PhD Director Academic Liaison Westminster Business Forum Drug Discovery 5 th Feb 2013 Royal Society, London GSK currently have no formal Position Statement on

SLIDE 1

Open Access to Scientific Data & Publications

Malcolm Skingle CBE DSc PhD

Director – Academic Liaison Drug Discovery

Westminster Business Forum 5th Feb 2013 Royal Society, London

SLIDE 2

GSK currently have no formal Position

Statement on pre-clinical scientific publication & APCs but support the principle of Open Access to scientific data

GSK share data, reagents & resources with

external parties in a bid to expand areas of the science base of value to the whole scientific community

The impact factors for GSK published papers

are comparable to those of academia.

SLIDE 3

Papers with GSK Author 2000-2012 100+ citations

Where GSK Authors have contributed to a paper that can be found in Scopus with over 100 citations

SLIDE 4

SLIDE 5

Open Innovation - Malaria

Attempts to generate leads vs malaria

– GSK screened 2 million compounds vs the malaria parasite P.falciparum to generate 13,500 hits – Took 5 GSK scientists 1 year to complete – GSK to publish the chemical structures & associated assay data – Data freely available via a user-friendly database

SLIDE 6

EMBL-EBI Database for Mining Malaria Compound Set - www.ebi.ac.uk/chemblntd

John Overington, EBI

SLIDE 7

SLIDE 8

“Open source” ‐ malaria screening

GSK Malaria Set “TCAMS” MMV Malaria Box (~50% from TCAMS)

Shared with ~14 groups Shared with ~100 groups

SLIDE 9

Thursday 11 October 2012, London UK GSK announces further initiatives to advance

penness and collaboration to help tackle

global health challenges

Tuberculosis (TB) ‘compound library’ to be

made available to help stimulate research into TB

Investment in GSK’s Tres Cantos Open Lab to

be doubled with an additional £5m funding awarded

SLIDE 10

Concluding Remarks

GSK are changing their internal structures to be

more open & transparent with the external science base.

We are keen to share our data with external

scientists in order to expand the science base. Open Access publishing is part of this continuum

The more science you share with others, the

more you get back from external sources

SLIDE 11